TLR4 Modulators Decouple Opioid Analgesia from Glial Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, particularly those involving opioids, often result in unwarranted dependency and side effects due to inadequate modulation of Toll-like receptor (TLR) activity, which contributes to neuropathic pain, opioid tolerance, and dependence.
Innovation Solution
Development of compounds that modulate TLR4 activity, specifically by administering a compound of formula I, which can be used in conjunction with opioids to inhibit TLR4 activity, thereby reducing opioid side effects and enhancing analgesic efficacy while minimizing dependency and tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid pharmacotherapy is used to treat pain, then pain relief is achieved, but dependency and side effects occur
Solution Approach 1:
The patent introduces TLR modulators as intermediary compounds that mediate between opioid administration and glial cell activation. These modulators selectively target TLR pathways in glial cells to prevent the harmful activation cascade while allowing opioid analgesic effects to proceed through neuronal opioid receptors, thus decoupling therapeutic benefit from harmful side effects
Solution Approach 2:
The invention applies local quality by selectively modulating TLR activity specifically in glial cells while leaving neuronal opioid receptor function unchanged. This spatial and cellular specificity allows the patent to address harmful glial activation without compromising the essential pain-relieving neuronal pathways
2Object-generated harmful factors
If TLR activity is not modulated, then opioid dependency develops, but without modulation, neuropathic pain persists
Solution Approach 1:
TLR modulators serve as intermediary agents that specifically intervene in the glial activation pathway triggered by opioids. By targeting TLR signaling in glial cells, these modulators prevent the development of dependency and tolerance while simultaneously addressing neuropathic pain components that arise from glial-mediated inflammation and sensitization
3Reliability
If high doses of opioids are administered to overcome tolerance, then analgesic effect is maintained, but dependency and side effects increase
Solution Approach 1:
The patent employs TLR modulators as intermediary compounds that prevent glial cell activation and the subsequent development of opioid tolerance. By blocking the TLR signaling pathway in glial cells, these modulators maintain opioid sensitivity at lower doses, preventing the need for dose escalation and thereby reducing dependency risk and side effects
Solution Approach 2:
The invention changes the pharmacological parameter landscape by introducing a new target (TLR pathway in glial cells) that regulates opioid response. This allows optimization of opioid dosing parameters by preventing tolerance development, thereby maintaining effective analgesia at lower, safer doses rather than requiring increasing doses to overcome tolerance
Data Source
Figure 1a~3A
Figure 3B~4
Figure 5A~5B
AI summary
The present invention provides a compound selected from the group consisting of: Formula (I) and Formula (II), where n, m, X1, X2, X3, X4, R1, R2, R3, R11, R12, Y1, Y2, Y3, Y4, and Y5 are those defined herein. Some aspects of the invention also provides methods for using these compounds and compositions comprising the same.